APP and Alzheimer disease: Recently, targeted DNAm of the APP promoter mediated by dCas9 fused with DNA methyltransferase 3 (Dnmt3) has been shown to reduce Aβ levels and improve cognitive and behavioural impairments in a mouse model of AD [131].